Houston regenerative medicine company opens new lab at UH

cell therapy innovation

FibroBiologics is opening a unique new lab at the University of Houston's Technology Bridge. Photo by Natalie Harms/InnovationMap

Pete O’Heeron wants you to know that “Bohemian Rhapsody” was originally released as a B-side. What does this nugget about Queen have to do with regenerative medicine? For O’Heeron and his company, FibroBiologics, it means everything.

That’s because most scientists consider stem cells the A-side when it comes to the race to curing disease. But FibroBiologics has set its sights on fibroblasts. The most common cell in the body, fibroblasts are the main cell type in connective tissue.

“Everyone was betting on stem cells, and we started betting on fibroblasts,” says O’Heeron, who started the company in 2008 as SpinalCyte. “I think what we're going to see is that fibroblasts are going to end up winning, there are more robust, more that are lower cost cell, they have higher therapeutic values, higher immune modulation. They're just a better overall cell than the than the stem cells.”

Since a neurosurgeon and a dermatologist first introduced O’Heeron to the idea of using fibroblasts to regrow discs in the spine, the company has expanded its reach to include promising treatments for multiple sclerosis and cancer and in wound care. Imagine a world where doctors lay fibroblasts directly onto surgical incisions after surgery, cutting the time for healing in half.

FibroBiologics has organically written and filed more than 320 patents.

“It's quite a unique situation. I don’t think that in other areas of science that you have such a wide open area to go out and patent. It's just it was a brand new area nobody had been working on,” O’Heeron explains.

And soon, investors will be able to own a stake in the impressive work being forged in Houston. FibroBiologics, previously FibroGenesis, was formed in order to go public in a direct NASDAQ listing. The goal is to access the capital necessary to go to human trials. Earlier this year, the company also launched a crowdfunding campaign.

“We’ve had really fantastic results with animals and now we’re ready for humans,” says O’Heeron. “We've done small human trials, but we haven't done the large ones that are going to get the commercialization approval from the FDA.”

With that in mind, the company just signed a deal with University of Houston’s Innovation Center. On Thursday, September 7, FibroBiologics will dedicate the Newlin-Linscomb Lab for Cell Therapies in the UH Technology Bridge. The new lab is named for former player and color commentator for the Houston Rockets, Mike Newlin and his wife, Cindy, as well as Pam and Dan Linscomb, a founding partner of Kuhl-Linscomb, one of the largest wealth management companies in Houston.

Other big local names newly attached to the company are astronaut Kate Rubins and Elizabeth Shpall, the director of the cell therapy laboratory at MD Anderson Cancer Center. Both have joined FibroBiologics as members of its scientific advisory board.

To fill the lab, O’Heeron says that he is adding to his team as quickly as he is able. The barrier is the fact that there are few, if any people in the world with the exact qualifications he’s seeking.

“Anytime you're breaking new scientific ground, you can't really just go out and recruit someone with that background because it really doesn't exist,” he says. But he is willing to teach and challenge scientists who are the right fit, and is hoping to expand the team in the new lab.

But like Queen did in 1975, FibroBiologics is pioneering a category of its own. And that’s something worth betting on.

From Your Site Articles
Space experts discussed the city's role in the space industry at a recent event. Photo via NASA

Overheard: Houston needs to strengthen infrastructure, workforce to maintain Space City status

eavesdropping in houston

In no time at all, humans will return to the moon and as they make the first spacewalks in fifty years — wearing suits designed in Houston — they will call down to earth, and only one city in the world will be named on the radio transmissions.

Houston is the Space City — but what will it take to maintain that moniker? This was a big topic of the Greater Houston Partnership's second annual State of Space event hosted on Tuesday, October 11.

A diverse and impressive panel discussed the Space City's future, the upcoming moon missions, commercializations, and more. If you missed the discussion, check out some key moments from the event.

"Houston has a significant role in all areas of Artemis."

— Vanessa Wyche, director of NASA's Johnson Space Center. "We have crew missions, robotic missions, and other technologies that will make up Artemis."

"The big mission we have is for Houston to remain the hub in human space flight moving forward."

— Wyche says, adding "for us to be the nexus and accelerator of research, innovation, and STEM, we need to work together for workforce development for the space economy."

"We're at a point were we can pivot to develop scalable products at a much lower cost — it really reduces the barrier of entry for commercial space partners."

— Peggy Guirgis, general manager of space systems for Collins Aerospace. "We're building in Houston because this is really an engineering hub," she adds, noting the industries and schools here that support the industry.

"Why Houston? Because of, more than anything, the sense of community."

— Steve Altemus, president and CEO of Intuitive Machines, noting the support behind building the Houston Spaceport and the existing Johnson Space Center, as well as all the other players within the space sector locally.

"At some point in the very near future we are going to land humans on the moon — the first woman on the moon, the first person of color on the moon — and we're going to say, 'Moon, Houston.' This is the only city in the world that's going to be said on those loops."

— Kate Rubins, NASA astronaut. "I feel very fortunate to be here."

"Right here in Houston — at the HoustonSpaceport, we're building a space where the Space Force can do classified work."

— Altemus says. "That's one area that I'd like to see grow."

"We need to continue to build a talent pipeline as well as generating a workforce that is able to keep pace with the rapidly growing space industry."

— Guirgis says.

"When people think about Houston, NASA has been the nexus and center of gravity, but all of Houston has been a magnet. It's a draw to come and work here."

— Rubins says. "One way to continue this is through infrastructure that's being built here — it's incredible. It's going to cement this as a place that you want to come if you're a commercial company and you want to partner with NASA, or you want to be a contractor for one of these other companies. ... And the startup scene is booming these days in Houston."

"We need to make sure that we have the world-class capabilities."

— Wyche says. "The workforce is so very important."

Here are three of the latest updates on new execs and advisory appointments from two Houston startups and a local venture group. Photo via Getty Images

3 Houston organizations announce strategic appointments across biotech and VC

short stories

Five Houston innovators have new roles they're excited about this spring. From new advisory board members to c-level execs, here's who's moving and shaking in Houston innovation.

The Artemis Fund names new vice president of finance and operations

Adrienne Mangual has a background in finance and consulting. Photo courtesy of Artemis

The Artemis Fund, a venture capital firm that funds female-founded startups with technology solutions in fintech, e-commerce tech, and care-tech, has announced a new member of its leadership.

Adrienne Mangual is the new vice president of finance and operations at the firm, joining Artemis's co-founders and general partners, Stephanie Campbell, Leslie Goldman, and Diana Murakhovskaya, along with Austin-based Juliette Richert, a senior analyst.

Mangual received her MBA from Rice University in 2019 after working 15 years in finance roles at J.P. Morgan and Key Energy Services. Over the past few years, she's worked in consulting positions with startups and technology.

"This is an exciting time to join The Artemis Fund as the fund is growing and our reach is expanding and continuing to make an impact on female founders," Mangual tells InnovationMap. "I am looking forward to supporting existing and future female founders and working with Diana, Stephanie, and Leslie as part of the team making investment decisions for the fund."

FibroBiologics appoints scientific advisory board member

Former astronaut Kate Rubins, who's spent a total of 300 days in space, has joined the a Houston company's scientific advisory board. Photo courtesy of FibroBiologics

Houston-based clinical-stage therapeutics company FibroBiologics announced the appointment of Kathleen “Kate” Rubins, Ph.D., to its scientific advisory board. A microbiologist and NASA astronaut, Rubins has conducted medical research on earth at academic institutions as well as on board the International Space Station.

“We are honored to welcome Dr. Rubins to our SAB,” says Pete O’Heeron, CEO and chairman of FibroBiologics, in a news release. “She has distinguished herself in both terrestrial research at the Salk and Whitehead Institutes and through her ethereal work on the International Space Station.

"It’s rare to have such a unique perspective on microbiology," he continues. "Dr. Rubins joins a board of world-renowned scientists who will help to guide us as we advance fibroblast cell-based therapeutics through preclinical and clinical development. We are the only company focused on this unique opportunity in leveraging fibroblasts as treatments for chronic diseases and Dr. Rubins will be a key advisor in our pursuit to bring relief to the patients.”

In 2016, Rubins completed her first spaceflight on Expedition 48/49, where she became the first person to sequence DNA in space. Most recently, she served on the ISS as a flight engineer for Expedition 63/64. Across her two flights, she has spent a total of 300 days in space, the fourth most days in space by a U.S. female astronaut, according to the release.

Cemvita Factory hires, promotes within its leadership team

Tara Karimi, co-founder and CTO, stands with Cemvita Factory's two new hires and recently promoted employee. Photo courtesy of Cemvita

Cemvita Factory has made big moves in its leadership team. The low-carbon biotech and synthetic biology solution provider has recently made three strategic appointments: Charles Nelson was hired as chief business officer, Roger A. Harris was promoted to chief commercial officer, and Alex Juminaga was recruited as head of strain development.

“Scaling to meet market demand requires the right team at the right time,” says Tara Karimi, co-founder and CTO of Cemvita, in a news release. “With Charlie, Roger, and Alex’s leadership, we’re well-positioned for growth at a time when the demand for decarbonization solutions is greater than ever.”

With over 10 years in product development, engineering, and technology commercialization experience, Nelson will oversee all aspects of sales, business development, and customer success.

“At Cemvita, we create sustainable solutions to challenges across heavy industries,” says Nelson in the release. “Our goal is to reinvent heavy industries in ways that speak to the future, reduce companies’ carbon footprints, and even create jobs; I’m delighted to help lead the charge.”

Harris originally joined Cemvita as vice president of technology commercialization a year ago and has over two decades of experience in research and development, and engineering. In his new role, he is responsible for scaling and commercializing the startup's technology.

“Cemvita is positioned incredibly well to support heavy industry in efforts to innovate, and to help oil and gas diversify offerings and reduce dependency on carbon-intensive products,” says Harris in the release. “It is an exciting time and I’m thrilled to be with Cemvita.”

Lastly, Alex Juminaga will lead the Cemvita biofoundry’s production of novel biomolecules. He brings over a decade of laboratory experience — specializing in metabolic engineering, protein expression/purification, enzyme kinetics and binding assays, analytical chemistry, and more.

“The field of synthetic biology is just getting started, with thousands of microbes yet to be discovered,” says Juminaga. “I’m excited to work alongside the brilliant scientists at Cemvita as we uncover new microbiomes and new uses for these tiny treasures.”

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Nominations are now open for the 2025 Houston Innovation Awards

Calling All Innovators

Calling all Houston innovators: The Houston Innovation Awards return this fall to celebrate the best and brightest in the Houston innovation ecosystem right now.

Presented by InnovationMap, the fifth annual Houston Innovation Awards will take place November 5 at TMC Helix Park.

The awards program will honor the top startups and innovators in Houston across 10 categories, and we're asking you to nominate the most deserving Houston innovators and innovative companies today.

This year's categories are:

  • Minority-founded Business, honoring an innovative startup founded or co-founded by BIPOC or LGBTQ+ representation.
  • Female-founded Business, honoring an innovative startup founded or co-founded by a woman.
  • Energy Transition Business, honoring an innovative startup providing a solution within renewables, climatetech, clean energy, alternative materials, circular economy, and beyond.
  • Health Tech Business, honoring an innovative startup within the health and medical technology sectors.
  • Deep Tech Business, honoring an innovative startup providing technology solutions based on substantial scientific or engineering challenges, including those in the AI, robotics, and space sectors.
  • Startup of the Year (People's Choice), honoring a startup celebrating a recent milestone or success. The winner will be selected by the community via an interactive voting experience.
  • Scaleup of the Year, honoring an innovative later-stage startup that's recently reached a significant milestone in company growth.
  • Incubator/Accelerator of the Year, honoring a local incubator or accelerator that is championing and fueling the growth of Houston startups.
  • Mentor of the Year, honoring an individual who dedicates their time and expertise to guide and support budding entrepreneurs.
  • Trailblazer, honoring an innovator who's made a lasting impact on the Houston innovation community.

Nominations may be made on behalf of yourself, your organization, and other leaders in the local innovation scene. The nomination period closes on August 31, so don't delay — nominate today at this link, or fill out the embedded form below.

Our panel of esteemed judges will review the nominations, and determine the finalists and winners. Finalists will be unveiled on September 30, and the 2025 Houston Innovation Awards winners will be announced live at our event on November 5.

Tickets will go on sale this fall. Stay tuned for that announcement, as well as more fanfare leading up to the 2025 Houston Innovation Awards.

Nominate now:

Interested in Innovation Awards sponsorship opportunities? Please contact sales@innovationmap.com.

Intuitive Machines blasts into next phase and more innovation news to know

Trending Topics

Editor's note: We're looking back at the top Houston innovation and business news for the first half of August 2025. Intuitive Machines has secured a new contract, a Japanese energy tech manufacturer now has a Houston HQ, tech jobs are on the rise, and more. Revisit InnovationMap's most-read stories from August 1-15 below:

1. Intuitive Machines lands $9.8M to complete orbital transfer vehicle

Intuitive Machines to acquire NASA-certified deep space navigation company

Intuitive Machines' orbital transfer vehicle project is entering its next phase. Photo via Getty Images.

Houston-based Intuitive Machines, which rang the NASDAQ opening bell July 31, has secured a $9.8 million Phase Two government contract for its orbital transfer vehicle. The contract will push the project through its Critical Design Review phase, which is the final engineering milestone before manufacturing can begin. Continue reading.

2. Japanese energy tech manufacturer moves U.S. headquarters to Houston

TMEIC Corporation Americas has moved its U.S. headquarters to Houston. Photo via tmeic.com

TMEIC Corporation Americas has officially relocated its headquarters from Roanoke, Virginia, to Houston. TMEIC Corporation Americas, a group company of Japan-based TMEIC Corporation Japan, recently inaugurated its new space in the Energy Corridor. The new HQ occupies the 10th floor at 1080 Eldridge Parkway, according to ConnectCRE. The company first announced the move last summer. Continue reading.

3. 11 can't-miss Houston business and innovation events for August

From insightful talks to a young professionals summit, here's what not to miss and how to register. Photo via Getty Images

The tech event scene is heating up in August. From insightful talks to a young professionals summit, we've rounded up the events not to miss and how to register. Continue reading.

4. Houston tech jobs to grow in 2025 as Texas leads U.S. in new tech employment

The Houston area is expected to employ 158,176 tech professionals this year, according to a new report by CompTIA. Photo via Getty Images.

Tech employment in the Houston metro area is expected to climb by more than two percent this year, according to a new projection. CompTIA’s State of the Tech Workforce 2025 report forecasts the Houston area will employ 158,176 tech professionals this year, compared with an estimated 154,905 last year. That would be an increase of 2.1 percent. Continue reading.

5. U.S. News ranks Houston hospital No. 1 in Texas for 14th year in a row

Houston Methodist is once again the top hospital in Texas. Photo via Houston Methodist

U.S. News & World Report has released its 2025 rankings of the best hospitals in Texas, and they prove that Houston is in good hands. The esteemed Houston Methodist Hospital was rated the No. 1 best hospital in Texas for the 14th consecutive year, and the No. 1 hospital in the metro area. Eleven more Houston-area hospitals earned spots among the statewide top 35. Continue reading.

MD Anderson launches $10M collaboration to advance personalized cancer treatment tech

fighting cancer

The University of Texas MD Anderson Cancer Center and Japan’s TOPPAN Holdings Inc. have announced a strategic collaboration to co-develop TOPPAN Holdings’ 3D cell culture, or organoid, technology known as invivoid.

The technology will be used as a tool for personalized cancer treatments and drug screening efforts, according to a release from MD Anderson. TOPPAN has committed $10 million over five years to advance the joint research activities.

“The strategic alliance with MD Anderson paves a promising path toward personalized cancer medicine," Hiroshi Asada, head of the Business Innovation Center at TOPPAN Holdings, said in a news release.

Invivoid is capable of establishing organoid models directly from patient biopsies or other tissues in a way that is faster and more efficient. Researchers may be able to test a variety of potential treatments in the laboratory to understand which approach may work best for the patient, if validated clinically.

“Organoids allow us to model the three-dimensional complexity of human cancers in the lab, thus allowing us to engineer a powerful translational engine—one that could not only predict how patients will respond to therapy before treatment begins but also could help to reimagine how we discover and validate next-generation therapies," Dr. Donna Hansel, division head of pathology and laboratory medicine at MD Anderson, added in the news release. “Through this collaboration, we hope to make meaningful progress in modeling cancer biology for therapeutic innovation.”

The collaboration will build upon preclinical research previously conducted by MD Anderson and TOPPAN. The organizations will work collaboratively to obtain College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA) certifications for the technology, which demonstrate a commitment to high-quality patient care. Once the certifications are obtained, they plan to conduct observational clinical studies and then prospective clinical studies.

“We believe our proprietary invivoid 3D cell culture technology, by enabling the rapid establishment of organoid models directly from patient biopsies, has strong potential to help identify more effective treatment options and reduce the likelihood of unnecessary therapies,” Asada added in the release. “Through collaboration on CAP/CLIA certification and clinical validation, we aim to bring this innovation closer to real-world patient care and contribute meaningfully to the advancement of cancer medicine."

View All Listings